Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
Nederlands Tijdschrift Voor Geneeskunde|October 13, 2009
[Medicinal use of cannabis in the Netherlands: towards a responsible pattern of use]Floris A de JongExpert Review of Anticancer Therapy|December 23, 2003
Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumorsFloris A de Jong, Jaap VerweijCancer Management and Research|July 29, 2024
Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating AgentsMarkus Joerger, Kira-Lee Koster, Tomas Janik, et al.European Journal of Cancer (Oxford, England : 1990)|January 22, 2008
Lifestyle habits as a contributor to anti-cancer treatment failureFloris A de Jong, Alex Sparreboom, Jaap Verweij, et al.The Oncologist|August 2, 2006
Complementary and alternative medicine during cancer treatment: beyond innocenceMetin Tascilar, Floris A de Jong, Jaap Verweij, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variabilityFloris A de Jong, Ron H J Mathijssen, Rujia Xie, et al.Cancer Letters|December 14, 2005
Role of pharmacogenetics in irinotecan therapyFloris A de Jong, Maja J A de Jonge, Jaap Verweij, et al.Cancer Treatment Reviews|March 1, 2014
Management of fatigue in patients with cancer -- a practical overviewRutger H T Koornstra, Marlies Peters, Stacey Donofrio, et al.Cancer Biology & Therapy|September 14, 2006
Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drainFloris A de Jong, Jos J E M Kitzen, Peter de Bruijn, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 3, 2003
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detectionFloris A de Jong, Ron H J Mathijssen, Peter de Bruijn, et al.Pageof 4